Interpretation of the surgical section of the 2024 first edition of the National Comprehensive Cancer Network (NCCN) guidelines for non-small cell lung cancer

doi:10.3877/cma.j.issn.2095-8773.2024.02.01

Abstract

Abstract:

Non-small cell lung cancer (NSCLC) represents a prevalent malignant neoplasm, with surgical resection serving as its primary therapeutic modality. Following a pivotal randomized trial released by the North American Lung Cancer Study Group in 1995, which demonstrated a heightened local recurrence rate and diminished survival in T1N0 stage lung cancer patients undergoing segmentectomy compared to lobectomy, the latter has since been acknowledged as the established surgical approach for achieving curative outcomes in early-stage NSCLC. Nevertheless, during the latter part of the 20th century, segmentectomy, renowned for its optimization of lung function preservation, progressively gained traction in the landscape of lung cancer treatment. Furthermore, the exploration of thoracoscopic techniques and robot-assisted surgery has emerged as a focal point in research. Substantial advancements have been witnessed in the realm of surgical treatment for NSCLC in recent years. This article endeavors to expound upon the surgical section of the 2024 first edition of the National Comprehensive Cancer Network (NCCN) guidelines for NSCLC, offering intricate elucidations pertaining to surgical indications, methodologies, lymph node dissection strategies, etc. Its overarching objective is to facilitate a nuanced comprehension among surgeons regarding the underlying principles and methodologies governing NSCLC surgical interventions.

Key words: Non-small cell lung cancer, National Comprehensive Cancer Network guidelines, Interpretation of guidelines

Kuan Xu, Heng Zhao, Bo Ye. Interpretation of the surgical section of the 2024 first edition of the National Comprehensive Cancer Network (NCCN) guidelines for non-small cell lung cancer[J]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2024, 11(02): 79-84.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxbwkdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-8773.2024.02.01

https://zhxbwkdzzz.cma-cmc.com.cn/EN/Y2024/V11/I02/79

References 30

1	Siegel RL，Miller KD，Jemal A．Cancer statistics, 2019[J]．CA Cancer J Clin，2019，69（1）：7-34．
2	Gao S，Li N，Wang S，et al．Lung Cancer in People's Republic of China[J]．J Thorac Oncol，2020，15（10）：1567-1576．
3	Cahan WG．Radical lobectomy[J]．J Thorac Cardiovasc Surg，1960，39：555-572．
4	Strand TE，Rostad H，Møller B，et al．Survival after resection for primary lung cancer: a population based study of 3211 resected patients[J]．Thorax，2006，61（8）：710-715．
5	Qiu C，Wang G，Xu J，et al．Sublobectomy versus lobectomy for stage I non-small cell lung cancer in the elderly[J]．Int J Surg，2017，37：1-7．
6	Yi E，Cho S，Kim K，et al．Comparison of survival outcomes between sublobar resection and lobectomies in early-stage lung adenocarcinoma by propensity score matching analysis[J]．Indian J Thorac Cardiovasc Surg，2020，36（4）：382-387．
7	Wald O，Sadeh BM，Bdolah-Abram T，et al．Outcomes of sublobar resection vs lobectomy for invasive clinical stage T1N0 non-small-cell lung cancer: A propensity-match analysis[J]．Cancer Rep (Hoboken)，2021，4（3）：e1339．
8	Nomori H，Yamazaki I，Machida Y，et al．Lobectomy versus segmentectomy: a propensity score-matched comparison of postoperative complications, pulmonary function and prognosis[J]．Interact Cardiovasc Thorac Surg，2022，34（1）：57-65．
9	Zhang B，Liu R，Ren D，et al．Comparison of Lobectomy and Sublobar Resection for Stage IA Elderly NSCLC Patients (≥70 Years): A Population-Based Propensity Score Matching's Study[J]．Front Oncol，2021，11：610638．
10	Saji H，Okada M，Tsuboi M，et al．Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial[J]．Lancet，2022，399（10335）：1607-1617．
11	Altorki N，Wang X，Kozono D，et al．Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer[J]．N Engl J Med，2023，388（6）：489-498．
12	Liang W，He J，Shen Y，et al．Impact of Examined Lymph Node Count on Precise Staging and Long-Term Survival of Resected Non-Small-Cell Lung Cancer: A Population Study of the US SEER Database and a Chinese Multi-Institutional Registry[J]．J Clin Oncol，2017，35（11）：1162-1170．
13	Akinbobola O，Ray MA，Fehnel C，et al．Institution-Level Evolution of Lung Cancer Resection Quality With Implementation of a Lymph Node Specimen Collection Kit[J]．J Thorac Oncol，2023，18（7）：858-868．
14	Nagata Y，Hiraoka M，Shibata T，et al．Prospective Trial of Stereotactic Body Radiation Therapy for Both Operable and Inoperable T1N0M0 Non-Small Cell Lung Cancer: Japan Clinical Oncology Group Study JCOG0403[J]．Int J Radiat Oncol Biol Phys，2015，93（5）：989-996．
15	van Meerbeeck JP，Kramer GW，Van Schil PE，et al．Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer[J]．J Natl Cancer Inst，2007，99（6）：442-450．
16	Albain KS，Swann RS，Rusch VW，et al．Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial[J]．Lancet，2009，374（9687）：379-386．
17	Martins RG，D'Amico TA，Loo BW Jr，et al．The management of patients with stage IIIA non-small cell lung cancer with N2 mediastinal node involvement[J]．J Natl Compr Canc Netw，2012，10（5）：599-613．
18	Chang JY，Mehran RJ，Feng L，et al．Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery[J]．Lancet Oncol，2021，22（10）：1448-1457．
19	Howington JA，Blum MG，Chang AC，et al．Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines[J]．Chest，2013，143（5 Suppl）：e278S-e313S．
20	Suzuki K，Asamura H，Kusumoto M，et al．"Early" peripheral lung cancer: prognostic significance of ground glass opacity on thin-section computed tomographic scan[J]．Ann Thorac Surg，2002，74（5）：1635-1639．
21	Suzuki K，Koike T，Asakawa T，et al．A prospective radiological study of thin-section computed tomography to predict pathological noninvasiveness in peripheral clinical IA lung cancer (Japan Clinical Oncology Group 0201)[J]．J Thorac Oncol，2011，6（4）：751-756．
22	Suzuki K，Watanabe SI，Wakabayashi M，et al．A single-arm study of sublobar resection for ground-glass opacity dominant peripheral lung cancer[J]．J Thorac Cardiovasc Surg，2022，163（1）：289-301.e2．
23	Aokage K，Saji H，Suzuki K，et al．A non-randomized confirmatory trial of segmentectomy for clinical T1N0 lung cancer with dominant ground glass opacity based on thin-section computed tomography (JCOG1211)[J]．Gen Thorac Cardiovasc Surg，2017，65（5）：267-272．
24	中华医学会肿瘤学分会，中华医学会杂志社．中华医学会肺癌临床诊疗指南(2023版)[J]．中华医学杂志，2023，103（27）：2037-2074．
25	Darling GE，Allen MS，Decker PA，et al．Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial[J]．J Thorac Cardiovasc Surg，2011，141（3）：662-670．
26	Hishida T，Miyaoka E，Yokoi K，et al．Lobe-Specific Nodal Dissection for Clinical Stage I and II NSCLC: Japanese Multi-Institutional Retrospective Study Using a Propensity Score Analysis[J]．J Thorac Oncol，2016，11（9）：1529-1537．
27	Adachi H，Sakamaki K，Nishii T，et al．Lobe-Specific Lymph Node Dissection as a Standard Procedure in Surgery for Non-Small Cell Lung Cancer: A Propensity Score Matching Study[J]．J Thorac Oncol，2017，12（1）：85-93．
28	Zhang Y，Fu F，Wen Z，et al．Segment Location and Ground Glass Opacity Ratio Reliably Predict Node-Negative Status in Lung Cancer[J]．Ann Thorac Surg，2020，109（4）：1061-1068．
29	Zhang Y，Deng C，Zheng Q，et al．Selective Mediastinal Lymph Node Dissection Strategy for Clinical T1N0 Invasive Lung Cancer: A Prospective, Multicenter, Clinical Trial[J]．J Thorac Oncol，2023，18（7）：931-939．
30	Edwards JG，Chansky K，Van Schil P，et al．The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor Descriptors for Non-Small Cell Lung Cancer[J]．J Thorac Oncol，2020，15（3）：344-359．

[1]	Zhen Wang, Lu Huang, Lianqun Lang, Lu Yue. Prognostic significance of platelet and albumin/fibrinogen ratio in second-line therapy of bevacizumab for advanced non-small cell lung cancer [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(01): 35-40.
[2]	Yating You, Zhoukui Bi, Liang Guo, Li Bai. Clinicopathological features and therapeutic efficacy of non-small cell lung cancer with uncommon EGFR mutation [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2023, 16(05): 635-639.
[3]	Tianxiu Wu, Yu Xu, Xiuqing Liao, Wei Yao, Guansong Wang, Yu Yang, Bin Wang, Liang Guo, Mingzhou Zhang, Guoming Wu, Li Luo, Li Bai, Yan Wang, Mingdong Hu, Zhi Xu. Relationship between BRCA1/2 gene mutation and efficacy of platinum-base chemotherapy in driver mutation-negative stage Ⅲ/Ⅳ non-small cell lung cancer [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2023, 16(05): 615-623.
[4]	Chenglu Huang, Fei Liao, Xianping Liu, Zhiqiang Wang. Relationship between overexpression of serum exosomal has_circ_0060937 and metastasis and poor prognosis of NSCLC [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2023, 16(04): 490-494.
[5]	Yiran Li, Yuxiu Wang, Yan Zhu, Meng Wang, Ying Liu, Wenjin Yan, Xingxiang Xu, Lingfeng Min. Analysis of differential genes that affect the efficacy of Nivolumab and Pembrolizumab in the treatment of non-small cell lung cancer based on GEO database [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2023, 16(01): 20-25.
[6]	Yuan Wang, Yi Yang, Yunfei Mou, Fuqiang Ren, Xin Huang. Analysis of postoperative osimertinib targeted therapy in patients with resectable non-small cell lung cancer [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2022, 15(05): 657-660.
[7]	Ling Ma, Yinglong Li, Na Yue, Lifei Yang. Expression and clinical value of differential proteins in exosomes from non-small cell lung cancer [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2022, 15(03): 327-330.
[8]	Jing Li, Guoyuan Ling, Shan Jiang, Xiaoju Chen, Xiaoyun Guo. Efficacy of pemetrexed delivery via ommaya capsule implantation versus lumbar puncture in treatment of leptomeningeal metastasis of non-small cell lung cancer [J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(02): 128-132.
[9]	Yang Li, Kunliang Guo, Bicheng Zhan, Quanquan Hu, Yuzhen Dai. Clinicopathological and molecular genetic characteristics and programmed cell death 1 ligand 1 expression in SMARCA4-deficient non-small cell lung cancer [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(12): 1309-1314.
[10]	Jiu Yang, Mei Hong, Zhiyuan Liu, Nuo Zhu. Yiqi Chutan recipe combined with chemotherapy for treatment of patients with advanced non-small cell lung cancer: short-term curative effect and impact on serum levels of IL-2 and TNF-α and immune function [J]. Chinese Journal of Clinicians(Electronic Edition), 2021, 15(12): 948-953.
[11]	Meisi Liang, Huimin Lan, Ting Yu, Shengqiao Li. The study of plumbagin on suppressing the proliferation of non-small cell lung cancer [J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2024, 12(02): 120-125.
[12]	Kexin Tang, Xi Lin, Hong Shan. Doxorubicin-loaded fluorescent carbon dots with PEI passivation inhibited proliferation, migration and invasion of non-small cell lung cancer cells [J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2022, 10(02): 131-136.
[13]	Leilei Shen, Yang Liu. The staging evolution and treatment strategies of stage ⅠB non-small cell lung cancer [J]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2022, 09(04): 246-254.
[14]	Xiao Liang, Lei Wang, Tao Jiang. Progress in surgical treatment of non-small cell lung cancer invading the chest wall [J]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2022, 09(03): 157-163.
[15]	Jianqiao Cai, Jing Huang, Lei Jiang. Double sleeve uniportal video-assisted thoracoscopic lobectomy—a retrospective study from shanghai pulmonary hospital [J]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2022, 09(03): 144-149.

Please choose a citation manager

Content to export